Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Agenus Community
NasdaqCM:AGEN Community
2
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Community Investing Ideas
Agenus
Popular
Undervalued
Overvalued
Agenus
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Precision Medicine And Global Aging Will Revolutionize Cancer Care
Key Takeaways Multiple transformative financing options and imminent investments could rapidly strengthen balance sheets and accelerate R&D, removing near-term funding concerns. Promising immunotherapy data, strong leadership, and strategic flexibility position the company for rapid market expansion, multi-indication approvals, and potential acquisition interest.
View narrative
US$23.00
FV
80.2% undervalued
intrinsic discount
14.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Agenus
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
Key Takeaways Strong clinical data and regulatory momentum could accelerate product approvals, drive significant market expansion, and improve near-term and long-term earnings potential. Strategic non-dilutive transactions and operational efficiencies bolster financial stability, enabling sustained R&D investment and enhancing margins and profitability prospects.
View narrative
US$11.00
FV
58.6% undervalued
intrinsic discount
7.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
about 18 hours ago
author updated this narrative
Your Valuation for
AGEN
AGEN
Agenus
Your Fair Value
US$
Current Price
US$4.55
39.0% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-263m
320m
2015
2018
2021
2024
2025
2027
2030
Revenue US$208.3m
Earnings US$43.4m
Advanced
Set Fair Value